Neumora Therapeutics is trading 6.04% lower at $0.52, with no confirmed company-specific announcement explaining the November 5 move.
- The reported November 5 earnings date is an estimate; it does not confirm results were released.
- The biotech sector is reported up 2.05%, contrary to the stock’s decline. Broader market weakness may be relevant, but sources do not establish it as the direct cause.
- Pre-market trading had been reported at $0.60, up 6.01%, before the live price context showed a reversal.